Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CanniMed 1:20
- Development stage
- Phase 1
- Lead developer
- Aurora Cannabis
- Modality
- Small Molecules
- Administration
- Oral, Sublingual
01
Overview
CanniMed 1:20 is a standardized medical cannabis oral oil characterized by a high concentration of cannabidiol (CBD) and a low concentration of delta-9-tetrahydrocannabinol (THC). Developed by CanniMed Therapeutics and now managed by Aurora Cannabis, the formulation typically contains 20 mg/mL of CBD and 1 mg/mL of THC. It is designed for therapeutic use in patients who require the anti-inflammatory, analgesic, and anticonvulsant properties of cannabinoids while minimizing the psychoactive effects associated with higher THC levels. The drug exerts its effects by interacting with the endocannabinoid system and other non-cannabinoid receptors. CBD acts as a negative allosteric modulator of the CB1 and CB2 receptors and as an agonist at the 5-HT1A serotonin receptor, while the low-dose THC component acts as a partial agonist at CB1 and CB2 receptors. This product is commonly utilized in Canada for the management of chronic pain, symptoms of multiple sclerosis, and certain types of treatment-resistant epilepsy.
- Brand names
- CanniMed 1:20
- Other names
- CanniMed 1:20 OilCanniMed 1:20 Oral Oil
02
Targets
ADRA1A (α1A)CYP2C19 (Cytochrome P450 2C19)Anandamide reuptake transporterTRPV1 (Transient receptor potential cation channel subfamily V member 1)MOR (Mu opioid receptor)CNR1 (Cannabinoid receptor 1)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))CYP3A4 (Cytochrome P450 3A4)Glycine receptorFAAHMICU1 (Mitochondrial calcium uptake protein 1)CaV3 (Caveolin-3)
Beyond the preview
Go deeper on CanniMed 1:20.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CanniMed 1:20.